Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 1Phase 2 Interventional Results available

Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer

ClinicalTrials.gov ID: NCT03310957

Public ClinicalTrials.gov record NCT03310957. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 21, 2026, 7:01 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Single Arm, Open Label Phase 1b/2 Study of SGN-LIV1A in Combination With Pembrolizumab for First-Line Treatment of Patients With Unresectable Locally-Advanced or Metastatic Triple-Negative Breast Cancer

Study identification

NCT ID
NCT03310957
Recruitment status
Completed
Study type
Interventional
Phase
Phase 1, Phase 2
Lead sponsor
Seagen Inc.
Industry
Enrollment
185 participants

Conditions and interventions

Interventions

  • ladiratuzumab vedotin Drug
  • Pembrolizumab Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 26, 2018
Primary completion
Sep 29, 2024
Completion
Sep 29, 2024
Last update posted
Dec 11, 2025

2018 – 2024

United States locations

U.S. sites
26
U.S. states
18
U.S. cities
24
Facility City State ZIP Site status
University of Alabama at Birmingham Birmingham Alabama 35249
Cedars Sinai Medical Center / Samuel Oschin Comprehensive Cancer Institute Los Angeles California 90048
Chao Family Comprehensive Cancer Center University of California Irvine Orange California 92868
University of California Irvine - Newport Orange California 92868
Rocky Mountain Cancer Centers - Aurora Aurora Colorado 80012
The Whittingham Cancer Center / Norwalk Hospital Norwalk Connecticut 06856
Helen F. Graham Cancer Center / Christiana Care Health Systems Newark Delaware 19713
Miami Cancer Institute at Baptist Health, Inc. Miami Florida 33176
AdventHealth Cancer Institute Orlando Florida 32804
H. Lee Moffitt Cancer Center and Research Institute Tampa Florida 33612
Piedmont Cancer Institute Atlanta Georgia 30309
Winship Cancer Institute / Emory University School of Medicine Atlanta Georgia 30322
Ingalls Cancer Care / Ingalls Memorial Hospital Harvey Illinois 60426
Cardinal Bernardin Cancer Center / Loyola University Medical Center Maywood Illinois 60153
University of Maryland Baltimore Maryland 21201
Allina Health Cancer Institute Minneapolis Minnesota 55407
Saint Luke's Cancer Institute LLC Kansas City Missouri 64111
Summit Medical Group Florham Park New Jersey 07932
New Mexico Cancer Center Albuquerque New Mexico 87131
Weill Cornell Medicine New York New York 10065
University of Pittsburgh Medical Center (UPMC)/Hillman Cancer Center Pittsburgh Pennsylvania 15232
Texas Oncology - DFW Dallas Texas 75246
Texas Oncology - Houston Memorial City Houston Texas 77024
Texas Oncology - San Antonio Medical Center Northeast San Antonio Texas 78212
University of Virginia Charlottesville Virginia 22903
Fred Hutchinson Cancer Center / Seattle Cancer Care Alliance / University of Washington Seattle Washington 98109-1023

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 24 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03310957, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 11, 2025 · Synced Jul 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03310957 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →